Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis

Dai, Yuzhao; He, He; Li, Sheyu; Lin-de, Yang; Wang, Xia; Liu, Zhi; An, Zhenmei

doi:10.3389/fendo.2020.622589

Cited by 20 publications

(18 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Also, particular consideration should be given to the potential benefits of antidiabetic drugs such as pioglitazone and sodium-glucose cotransporter 2 (SGLT2) inhibitors, which have been shown to be effective in patients with concurrent T2D and NAFLD [164,165], although larger RCTs are required. Similarly, the use of the glucagon-like peptide 1 (GLP-1) receptor agonists such as liraglutide or semaglutide is very promising as there is evidence that these agents impact liver histology and can also improve cardiovascular outcomes in patients with T2D [166][167][168][169]. Finally, as T2D itself is heterogeneous in its etiology, pathogenesis, and clinical presentation, precision medicine approaches to treat and prevent the disease are being actively investigated but significant barriers to their implementation and research gaps still exist [170].…”

Section: Type 2 Diabetesmentioning

confidence: 99%

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Lonardo¹,

Arab

Arrese

2021

Adv Ther

View full text Add to dashboard Cite

Precision medicine defines the attempt to identify the most effective approaches for specific subsets of patients based on their genetic background, clinical features, and environmental factors. Nonalcoholic fatty liver disease (NAFLD) encompasses the alcohol-like spectrum of liver disorders (steatosis, steatohepatitis with/without fibrosis, and cirrhosis and hepatocellular carcinoma) in the nonalcoholic patient. Recently, disease renaming to MAFLD [metabolic (dysfunction)-associated fatty liver disease] and positive criteria for diagnosis have been proposed. This review article is specifically devoted to envisaging some clues that may be useful to implementing a precision medicine-oriented approach in research and clinical practice. To this end, we focus on how sex and reproductive status, genetics, intestinal microbiota diversity, endocrine and metabolic status, as well as physical activity may interact in determining NAFLD/ MAFLD heterogeneity. All these factors should be considered in the individual patient with the aim of implementing an individualized therapeutic plan. The impact of considering NAFLD heterogeneity on the development of targeted therapies for NAFLD subgroups is also extensively discussed.

show abstract

Section: Type 2 Diabetesmentioning

confidence: 99%

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Lonardo¹,

Arab

Arrese

2021

Adv Ther

View full text Add to dashboard Cite

show abstract

“…However, these unbalanced production of PPARs may contribute to insulin resistance and metabolic syndrome ( Liss and Finck, 2017 ; Corrales et al, 2018 ), supporting the use of PPAR agonists to treat NAFLD ( Seo et al, 2008 ; Yoo et al, 2021 ). The utilization Glucagon-likepeptide-1 (GLP-1) receptor agonists is another therapeutic strategy currently explored in clinical trials ( Dai et al, 2020 ; Lv et al, 2020 ). GLP-1 is secreted by enteroendocrine cells after meal ingestion to potentiate insulin secretion and suppress glucagon production.…”

Section: Homeostatic Dysfunctions In Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

“…GLP-1 is secreted by enteroendocrine cells after meal ingestion to potentiate insulin secretion and suppress glucagon production. The secreted bioactive forms act systemically, since the GLP-1 receptor (GLP-1R) is expressed in a number of tissues ( Dai et al, 2020 ). The utilization of GLP-1R agonists exhibiting a longer half-life compare to that of the genuine hormone has been approved for T2DM treatment ( Andersen et al, 2018 ).…”

Section: Homeostatic Dysfunctions In Non-alcoholic Fatty Liver Diseasementioning

confidence: 99%

Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases

Moraes

Montagne

2021

Front. Physiol.

View full text Add to dashboard Cite

Animal experimentation is limited by unethical procedures, time-consuming protocols, and high cost. Thus, the development of innovative approaches for disease treatment based on alternative models in a fast, safe, and economic manner is an important, yet challenging goal. In this paradigm, the fruit-fly Drosophila melanogaster has become a powerful model for biomedical research, considering its short life cycle and low-cost maintenance. In addition, biological processes are conserved and homologs of ∼75% of human disease-related genes are found in the fruit-fly. Therefore, this model has been used in innovative approaches to evaluate and validate the functional activities of candidate molecules identified via in vitro large-scale analyses, as putative agents to treat or reverse pathological conditions. In this context, Drosophila offers a powerful alternative to investigate the molecular aspects of liver diseases, since no effective therapies are available for those pathologies. Non-alcoholic fatty liver disease is the most common form of chronic hepatic dysfunctions, which may progress to the development of chronic hepatitis and ultimately to cirrhosis, thereby increasing the risk for hepatocellular carcinoma (HCC). This deleterious situation reinforces the use of the Drosophila model to accelerate functional research aimed at deciphering the mechanisms that sustain the disease. In this short review, we illustrate the relevance of using the fruit-fly to address aspects of liver pathologies to contribute to the biomedical area.

show abstract

“…Its multisystemic pattern is due to a pro‐inflammatory state, oxidative stress, haemodynamic dysfunction, and ischaemia, which overlap in ‘dysmetabolic’ patients. This results in multiple clinical entities, such as cardiovascular diseases (CVD), 9 non‐alcoholic steatohepatitis 10,11 and other liver dysfunctions, 12,13 chronic kidney disease, 14,15 many cancer types, 16 and neurodegenerative disorders (Figure 1). 17,18 …”

Section: Introductionmentioning

confidence: 99%

Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors

Rossi

Barbalho

Araújo

et al. 2021

Diabetes Metabolism Res

234

134

View full text Add to dashboard Cite

Metabolic syndrome (MS) is a chronic non‐infective syndrome characterised clinically by a set of vascular risk factors that include insulin resistance, hypertension, abdominal obesity, impaired glucose metabolism, and dyslipidaemia. These risk factors are due to a pro‐inflammatory state, oxidative stress, haemodynamic dysfunction, and ischaemia, which overlap in ‘dysmetabolic’ patients. This review aimed to evaluate the relationship between the traditional components of MS with cardiovascular disease (CVD), inflammation, and oxidative stress. MEDLINE‐PubMed, EMBASE, and Cochrane databases were searched. Chronic low‐grade inflammatory states and metaflammation are often accompanied by metabolic changes directly related to CVD incidence, such as diabetes mellitus, hypertension, and obesity. Moreover, the metaflammation is characterised by an increase in the serum concentration of pro‐inflammatory cytokines, mainly interleukin‐1 β (IL‐1β), IL‐6, and tumour necrosis factor‐α (TNF‐α), originating from the chronically inflamed adipose tissue and associated with oxidative stress. The increase of reactive oxygen species overloads the antioxidant systems causing post‐translational alterations of proteins, lipids, and DNA leading to oxidative stress. Hyperglycaemia contributes to the increase in oxidative stress and the production of advanced glycosylation end products (AGEs) which are related to cellular and molecular dysfunction. Oxidative stress and inflammation are associated with cellular senescence and CVD. CVD should not be seen only as being triggered by classical MS risk factors. Atherosclerosis is a multifactorial pathological process with several triggering and aetiopathogenic mechanisms. Its medium and long‐term repercussions, however, invariably constitute a significant cause of morbidity and mortality. Implementing preventive and therapeutic measures against oxy‐reductive imbalances and metaflammation states has unquestionable potential for favourable clinical outcomes in cardiovascular medicine.

show abstract

Comparison of the Efficacy of Glucagon-Like Peptide-1 Receptor Agonists in Patients With Metabolic Associated Fatty Liver Disease: Updated Systematic Review and Meta-Analysis

Cited by 20 publications

References 37 publications

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Perspectives on Precision Medicine Approaches to NAFLD Diagnosis and Management

Drosophila melanogaster: A Powerful Tiny Animal Model for the Study of Metabolic Hepatic Diseases

Metabolic syndrome and cardiovascular diseases: Going beyond traditional risk factors

Contact Info

Product

Resources

About